drugset / Trial / NCT03635957

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957

Phase 4 Completed 14 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The overall objective of the study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of the concomitant use of pegloticase with methotrexate (MTX) to enhance the response rate seen with pegloticase alone in adults with uncontrolled gout.

Timeline

Start
2018-09-26
Primary completion
2019-10-23
Completion
2020-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 15 mg Oral
Subject Pegloticase Protein / enzyme biologic 8 mg Intravenous
Background Acetaminophen Small molecule 1000 mg Oral
Background Fexofenadine Unknown 60 mg Oral
Background Fexofenadine Unknown 180 mg Oral
Background Hydrocortisone Other / unclassified 200 mg Intravenous
Background Methylprednisolone Other / unclassified 125 mg Intravenous
Background folic acid Other / unclassified 1 mg Oral

Indications